世界の4価髄膜炎菌ワクチン市場予測 2023年-2029年

【英語タイトル】Global Quadrivalent Meningococcal Vaccine Market Growth 2023-2029

LP Informationが出版した調査資料(LP23DC00098)・商品コード:LP23DC00098
・発行会社(調査会社):LP Information
・発行日:2023年11月
・ページ数:94
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール(受注後2-3営業日)
・調査対象地域:グローバル、日本、アメリカ、ヨーロッパ、アジア、中国など
・産業分野:医薬品&医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD3,660 ⇒換算¥549,000見積依頼/購入/質問フォーム
Multi User(20名様閲覧用)USD5,490 ⇒換算¥823,500見積依頼/購入/質問フォーム
Corporate User(閲覧人数制限なし)USD7,320 ⇒換算¥1,098,000見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・送付(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
❖ レポートの概要 ❖

LPインフォメーションの最新刊調査レポート「世界の4価髄膜炎菌ワクチン市場」は、過去の販売実績から2022年の世界の4価髄膜炎菌ワクチンの総販売量を検討し、2023年から2029年の予測される4価髄膜炎菌ワクチンの販売量を地域別・市場分野別に包括的に分析しています。本調査レポートでは、地域別、市場分野別、サブセクター別の4価髄膜炎菌ワクチンの市場規模を掲載し、XXX百万米ドル規模の世界の4価髄膜炎菌ワクチン市場の詳細な分析を提供します。本インサイトレポートは、世界の4価髄膜炎菌ワクチン業界を包括的に分析し、製品セグメント、企業情報、売上、市場シェア、最新動向、M&A活動に関する主要トレンドを明らかにしています。
また、本レポートでは、加速する世界の4価髄膜炎菌ワクチン市場における各社の独自のポジションをより深く理解するために、4価髄膜炎菌ワクチン製品ポートフォリオ、能力、市場参入戦略、市場でのポジション、海外展開に焦点を当て、主要なグローバル企業の戦略を分析しています。

世界の4価髄膜炎菌ワクチン市場規模は、2022年のXXX百万米ドルから2029年にはXXX百万米ドルに成長すると予測され、2023年から2029年までの年平均成長率は000%と予測されます。4価髄膜炎菌ワクチンの米国市場は、2022年のXXX百万米ドルから2029年にはXXX百万米ドルに増加し、2023年から2029年までのCAGRは000%と予測されています。4価髄膜炎菌ワクチンの中国市場は、2023年から2029年までの年平均000%成長率で、2022年のXXX百万米ドルから2029年にはXXX百万米ドルに増加すると推定されます。4価髄膜炎菌ワクチンのヨーロッパ市場は、2023年から2029年にかけて年平均000%成長率で、2022年のXXX百万米ドルから2029年にはXXX百万米ドルに増加すると推定されています。

4価髄膜炎菌ワクチンの世界主要メーカーとしては、Sanofi-Pasteur、 Walvax、 Chengdu Kanghua Biological Products Co., Ltd.、 Beijing Zhifei Green Bamboo Biopharmaceutical Co., Ltd.、 Zhejiang Tianyuan Biopharmaceutical Co., Ltd.、 Beijing Institute of Biological Products Co., Ltd.、 CanSino Biological Co., Ltd.、 Hualan Biological Vaccine Co., Ltd.、 Amy Weixin Biopharmaceutical (Zhejiang) Co., Ltd.などを掲載しており、売上の面では、世界の2大企業が2022年にほぼ000%のシェアを占めています。

本レポートでは、製品タイプ、用途、主要メーカー、主要地域、国別の4価髄膜炎菌ワクチン市場の包括的な概要、市場シェア、成長機会などの情報を提供しています。

【市場細分化】

この調査では4価髄膜炎菌ワクチン市場をセグメンテーションし、種類別 (多糖体ワクチン、複合体ワクチン)、用途別 (病院、診療所)、および地域別 (アジア太平洋、南北アメリカ、ヨーロッパ、および中東・アフリカ) の市場規模を予測しています。

・種類別区分:多糖体ワクチン、複合体ワクチン

・用途別区分:病院、診療所

・地域別区分
南北アメリカ(アメリカ、カナダ、メキシコ、ブラジル)
アジア太平洋(中国、日本、韓国、東南アジア、インド、オーストラリア)
ヨーロッパ(ドイツ、フランス、イギリス、イタリア、ロシア)
中東・アフリカ(エジプト、南アフリカ、イスラエル、トルコ、GCC諸国)

【本レポートで扱う主な質問】

・世界の4価髄膜炎菌ワクチン市場の10年間の市場状況・展望は?
・世界および地域別に見た4価髄膜炎菌ワクチン市場成長の要因は何か?
・4価髄膜炎菌ワクチンの市場機会はエンドマーケットの規模によってどのように変化するのか?
・4価髄膜炎菌ワクチンのタイプ別、用途別の内訳は?
・新型コロナウイルス感染症とロシア・ウクライナ戦争の影響は?

********* 目次 *********

レポートの範囲
・市場の紹介
・分析対象期間
・調査の目的
・調査手法
・調査プロセスおよびデータソース
・経済指標
・通貨

エグゼクティブサマリー
・世界市場の概要:4価髄膜炎菌ワクチンの年間販売量2018-2029、地域別現状・将来分析
・4価髄膜炎菌ワクチンの種類別セグメント:多糖体ワクチン、複合体ワクチン
・4価髄膜炎菌ワクチンの種類別販売量:2018-2023年の販売量、売上、市場シェア、販売価格
・4価髄膜炎菌ワクチンの用途別セグメント:病院、診療所
・4価髄膜炎菌ワクチンの用途別販売量:2018-2023年の販売量、売上、市場シェア、販売価格

企業別世界の4価髄膜炎菌ワクチン市場
・企業別のグローバル4価髄膜炎菌ワクチン市場データ:2018-2023年の年間販売量、市場シェア
・企業別の4価髄膜炎菌ワクチンの年間売上:2018-2023年の売上、市場シェア
・企業別の4価髄膜炎菌ワクチン販売価格
・主要企業の4価髄膜炎菌ワクチン生産地域、販売地域、製品タイプ
・市場集中度分析
・新製品および潜在的な参加者
・合併と買収、拡大

4価髄膜炎菌ワクチンの地域別レビュー
・地域別の4価髄膜炎菌ワクチン市場規模2018-2023:年間販売量、売上
・主要国別の4価髄膜炎菌ワクチン市場規模2018-2023:年間販売量、売上
・南北アメリカの4価髄膜炎菌ワクチン販売の成長
・アジア太平洋の4価髄膜炎菌ワクチン販売の成長
・ヨーロッパの4価髄膜炎菌ワクチン販売の成長
・中東・アフリカの4価髄膜炎菌ワクチン販売の成長

南北アメリカ市場
・南北アメリカの国別の4価髄膜炎菌ワクチン販売量、売上(2018-2023)
・南北アメリカの4価髄膜炎菌ワクチンの種類別販売量
・南北アメリカの4価髄膜炎菌ワクチンの用途別販売量
・アメリカ市場
・カナダ市場
・メキシコ市場
・ブラジル市場

アジア太平洋市場
・アジア太平洋の国別の4価髄膜炎菌ワクチン販売量、売上(2018-2023)
・アジア太平洋の4価髄膜炎菌ワクチンの種類別販売量
・アジア太平洋の4価髄膜炎菌ワクチンの用途別販売量
・中国市場
・日本市場
・韓国市場
・東南アジア市場
・インド市場
・オーストラリア市場
・台湾市場

ヨーロッパ市場
・ヨーロッパの国別の4価髄膜炎菌ワクチン販売量、売上(2018-2023)
・ヨーロッパの4価髄膜炎菌ワクチンの種類別販売量
・ヨーロッパの4価髄膜炎菌ワクチンの用途別販売量
・ドイツ市場
・フランス市場
・イギリス市場
・イタリア市場
・ロシア市場

中東・アフリカ市場
・中東・アフリカの国別の4価髄膜炎菌ワクチン販売量、売上(2018-2023)
・中東・アフリカの4価髄膜炎菌ワクチンの種類別販売量
・中東・アフリカの4価髄膜炎菌ワクチンの用途別販売量
・エジプト市場
・南アフリカ市場
・イスラエル市場
・トルコ市場
・GCC諸国市場

市場の成長要因、課題、動向
・市場の成長要因および成長機会分析
・市場の課題およびリスク
・市場動向

製造コスト構造分析
・原材料とサプライヤー
・4価髄膜炎菌ワクチンの製造コスト構造分析
・4価髄膜炎菌ワクチンの製造プロセス分析
・4価髄膜炎菌ワクチンの産業チェーン構造

マーケティング、販売業者および顧客
・販売チャンネル:直接販売チャンネル、間接販売チャンネル
・4価髄膜炎菌ワクチンの主要なグローバル販売業者
・4価髄膜炎菌ワクチンの主要なグローバル顧客

地域別の4価髄膜炎菌ワクチン市場予測レビュー
・地域別の4価髄膜炎菌ワクチン市場規模予測(2024-2029)
・南北アメリカの国別予測
・アジア太平洋の国別予測
・ヨーロッパの国別予測
・4価髄膜炎菌ワクチンの種類別市場規模予測
・4価髄膜炎菌ワクチンの用途別市場規模予測

主要企業分析
Sanofi-Pasteur、 Walvax、 Chengdu Kanghua Biological Products Co., Ltd.、 Beijing Zhifei Green Bamboo Biopharmaceutical Co., Ltd.、 Zhejiang Tianyuan Biopharmaceutical Co., Ltd.、 Beijing Institute of Biological Products Co., Ltd.、 CanSino Biological Co., Ltd.、 Hualan Biological Vaccine Co., Ltd.、 Amy Weixin Biopharmaceutical (Zhejiang) Co., Ltd.
・企業情報
・4価髄膜炎菌ワクチン製品
・4価髄膜炎菌ワクチン販売量、売上、価格、粗利益(2018-2023)
・主要ビジネス概要
・最新動向

調査結果および結論

The global Quadrivalent Meningococcal Vaccine market size is projected to grow from US$ 181 million in 2022 to US$ 273.9 million in 2029; it is expected to grow at a CAGR of 6.1% from 2023 to 2029.
Many countries have implemented meningococcal vaccination programs, especially targeting high-risk groups such as infants, adolescents and university students. Inclusion or recommendation of quadrivalent meningococcal vaccines in national immunization schedules can significantly influence the market demand.
The meningococcal quadrivalent vaccine protects against 4 types of meningococcus: types A, C, Y, and W.
LPI (LP Information)’ newest research report, the “Quadrivalent Meningococcal Vaccine Industry Forecast” looks at past sales and reviews total world Quadrivalent Meningococcal Vaccine sales in 2022, providing a comprehensive analysis by region and market sector of projected Quadrivalent Meningococcal Vaccine sales for 2023 through 2029. With Quadrivalent Meningococcal Vaccine sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Quadrivalent Meningococcal Vaccine industry.
This Insight Report provides a comprehensive analysis of the global Quadrivalent Meningococcal Vaccine landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Quadrivalent Meningococcal Vaccine portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Quadrivalent Meningococcal Vaccine market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Quadrivalent Meningococcal Vaccine and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Quadrivalent Meningococcal Vaccine.
This report presents a comprehensive overview, market shares, and growth opportunities of Quadrivalent Meningococcal Vaccine market by product type, application, key manufacturers and key regions and countries.
Market Segmentation:
Segmentation by type
Polysaccharide Vaccine
Conjugate Vaccine
Segmentation by application
Hospital
Clinic
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company’s coverage, product portfolio, its market penetration.
Sanofi-Pasteur
Walvax
Chengdu Kanghua Biological Products Co., Ltd.
Beijing Zhifei Green Bamboo Biopharmaceutical Co., Ltd.
Zhejiang Tianyuan Biopharmaceutical Co., Ltd.
Beijing Institute of Biological Products Co., Ltd.
CanSino Biological Co., Ltd.
Hualan Biological Vaccine Co., Ltd.
Amy Weixin Biopharmaceutical (Zhejiang) Co., Ltd.
Key Questions Addressed in this Report
What is the 10-year outlook for the global Quadrivalent Meningococcal Vaccine market?
What factors are driving Quadrivalent Meningococcal Vaccine market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Quadrivalent Meningococcal Vaccine market opportunities vary by end market size?
How does Quadrivalent Meningococcal Vaccine break out type, application?
What are the influences of COVID-19 and Russia-Ukraine war?

❖ レポートの目次 ❖

1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Quadrivalent Meningococcal Vaccine Annual Sales 2018-2029
2.1.2 World Current & Future Analysis for Quadrivalent Meningococcal Vaccine by Geographic Region, 2018, 2022 & 2029
2.1.3 World Current & Future Analysis for Quadrivalent Meningococcal Vaccine by Country/Region, 2018, 2022 & 2029
2.2 Quadrivalent Meningococcal Vaccine Segment by Type
2.2.1 Polysaccharide Vaccine
2.2.2 Conjugate Vaccine
2.3 Quadrivalent Meningococcal Vaccine Sales by Type
2.3.1 Global Quadrivalent Meningococcal Vaccine Sales Market Share by Type (2018-2023)
2.3.2 Global Quadrivalent Meningococcal Vaccine Revenue and Market Share by Type (2018-2023)
2.3.3 Global Quadrivalent Meningococcal Vaccine Sale Price by Type (2018-2023)
2.4 Quadrivalent Meningococcal Vaccine Segment by Application
2.4.1 Hospital
2.4.2 Clinic
2.5 Quadrivalent Meningococcal Vaccine Sales by Application
2.5.1 Global Quadrivalent Meningococcal Vaccine Sale Market Share by Application (2018-2023)
2.5.2 Global Quadrivalent Meningococcal Vaccine Revenue and Market Share by Application (2018-2023)
2.5.3 Global Quadrivalent Meningococcal Vaccine Sale Price by Application (2018-2023)
3 Global Quadrivalent Meningococcal Vaccine by Company
3.1 Global Quadrivalent Meningococcal Vaccine Breakdown Data by Company
3.1.1 Global Quadrivalent Meningococcal Vaccine Annual Sales by Company (2018-2023)
3.1.2 Global Quadrivalent Meningococcal Vaccine Sales Market Share by Company (2018-2023)
3.2 Global Quadrivalent Meningococcal Vaccine Annual Revenue by Company (2018-2023)
3.2.1 Global Quadrivalent Meningococcal Vaccine Revenue by Company (2018-2023)
3.2.2 Global Quadrivalent Meningococcal Vaccine Revenue Market Share by Company (2018-2023)
3.3 Global Quadrivalent Meningococcal Vaccine Sale Price by Company
3.4 Key Manufacturers Quadrivalent Meningococcal Vaccine Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Quadrivalent Meningococcal Vaccine Product Location Distribution
3.4.2 Players Quadrivalent Meningococcal Vaccine Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 World Historic Review for Quadrivalent Meningococcal Vaccine by Geographic Region
4.1 World Historic Quadrivalent Meningococcal Vaccine Market Size by Geographic Region (2018-2023)
4.1.1 Global Quadrivalent Meningococcal Vaccine Annual Sales by Geographic Region (2018-2023)
4.1.2 Global Quadrivalent Meningococcal Vaccine Annual Revenue by Geographic Region (2018-2023)
4.2 World Historic Quadrivalent Meningococcal Vaccine Market Size by Country/Region (2018-2023)
4.2.1 Global Quadrivalent Meningococcal Vaccine Annual Sales by Country/Region (2018-2023)
4.2.2 Global Quadrivalent Meningococcal Vaccine Annual Revenue by Country/Region (2018-2023)
4.3 Americas Quadrivalent Meningococcal Vaccine Sales Growth
4.4 APAC Quadrivalent Meningococcal Vaccine Sales Growth
4.5 Europe Quadrivalent Meningococcal Vaccine Sales Growth
4.6 Middle East & Africa Quadrivalent Meningococcal Vaccine Sales Growth
5 Americas
5.1 Americas Quadrivalent Meningococcal Vaccine Sales by Country
5.1.1 Americas Quadrivalent Meningococcal Vaccine Sales by Country (2018-2023)
5.1.2 Americas Quadrivalent Meningococcal Vaccine Revenue by Country (2018-2023)
5.2 Americas Quadrivalent Meningococcal Vaccine Sales by Type
5.3 Americas Quadrivalent Meningococcal Vaccine Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Quadrivalent Meningococcal Vaccine Sales by Region
6.1.1 APAC Quadrivalent Meningococcal Vaccine Sales by Region (2018-2023)
6.1.2 APAC Quadrivalent Meningococcal Vaccine Revenue by Region (2018-2023)
6.2 APAC Quadrivalent Meningococcal Vaccine Sales by Type
6.3 APAC Quadrivalent Meningococcal Vaccine Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Quadrivalent Meningococcal Vaccine by Country
7.1.1 Europe Quadrivalent Meningococcal Vaccine Sales by Country (2018-2023)
7.1.2 Europe Quadrivalent Meningococcal Vaccine Revenue by Country (2018-2023)
7.2 Europe Quadrivalent Meningococcal Vaccine Sales by Type
7.3 Europe Quadrivalent Meningococcal Vaccine Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Quadrivalent Meningococcal Vaccine by Country
8.1.1 Middle East & Africa Quadrivalent Meningococcal Vaccine Sales by Country (2018-2023)
8.1.2 Middle East & Africa Quadrivalent Meningococcal Vaccine Revenue by Country (2018-2023)
8.2 Middle East & Africa Quadrivalent Meningococcal Vaccine Sales by Type
8.3 Middle East & Africa Quadrivalent Meningococcal Vaccine Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Quadrivalent Meningococcal Vaccine
10.3 Manufacturing Process Analysis of Quadrivalent Meningococcal Vaccine
10.4 Industry Chain Structure of Quadrivalent Meningococcal Vaccine
11 Marketing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Quadrivalent Meningococcal Vaccine Distributors
11.3 Quadrivalent Meningococcal Vaccine Customer
12 World Forecast Review for Quadrivalent Meningococcal Vaccine by Geographic Region
12.1 Global Quadrivalent Meningococcal Vaccine Market Size Forecast by Region
12.1.1 Global Quadrivalent Meningococcal Vaccine Forecast by Region (2024-2029)
12.1.2 Global Quadrivalent Meningococcal Vaccine Annual Revenue Forecast by Region (2024-2029)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Quadrivalent Meningococcal Vaccine Forecast by Type
12.7 Global Quadrivalent Meningococcal Vaccine Forecast by Application
13 Key Players Analysis
13.1 Sanofi-Pasteur
13.1.1 Sanofi-Pasteur Company Information
13.1.2 Sanofi-Pasteur Quadrivalent Meningococcal Vaccine Product Portfolios and Specifications
13.1.3 Sanofi-Pasteur Quadrivalent Meningococcal Vaccine Sales, Revenue, Price and Gross Margin (2018-2023)
13.1.4 Sanofi-Pasteur Main Business Overview
13.1.5 Sanofi-Pasteur Latest Developments
13.2 Walvax
13.2.1 Walvax Company Information
13.2.2 Walvax Quadrivalent Meningococcal Vaccine Product Portfolios and Specifications
13.2.3 Walvax Quadrivalent Meningococcal Vaccine Sales, Revenue, Price and Gross Margin (2018-2023)
13.2.4 Walvax Main Business Overview
13.2.5 Walvax Latest Developments
13.3 Chengdu Kanghua Biological Products Co., Ltd.
13.3.1 Chengdu Kanghua Biological Products Co., Ltd. Company Information
13.3.2 Chengdu Kanghua Biological Products Co., Ltd. Quadrivalent Meningococcal Vaccine Product Portfolios and Specifications
13.3.3 Chengdu Kanghua Biological Products Co., Ltd. Quadrivalent Meningococcal Vaccine Sales, Revenue, Price and Gross Margin (2018-2023)
13.3.4 Chengdu Kanghua Biological Products Co., Ltd. Main Business Overview
13.3.5 Chengdu Kanghua Biological Products Co., Ltd. Latest Developments
13.4 Beijing Zhifei Green Bamboo Biopharmaceutical Co., Ltd.
13.4.1 Beijing Zhifei Green Bamboo Biopharmaceutical Co., Ltd. Company Information
13.4.2 Beijing Zhifei Green Bamboo Biopharmaceutical Co., Ltd. Quadrivalent Meningococcal Vaccine Product Portfolios and Specifications
13.4.3 Beijing Zhifei Green Bamboo Biopharmaceutical Co., Ltd. Quadrivalent Meningococcal Vaccine Sales, Revenue, Price and Gross Margin (2018-2023)
13.4.4 Beijing Zhifei Green Bamboo Biopharmaceutical Co., Ltd. Main Business Overview
13.4.5 Beijing Zhifei Green Bamboo Biopharmaceutical Co., Ltd. Latest Developments
13.5 Zhejiang Tianyuan Biopharmaceutical Co., Ltd.
13.5.1 Zhejiang Tianyuan Biopharmaceutical Co., Ltd. Company Information
13.5.2 Zhejiang Tianyuan Biopharmaceutical Co., Ltd. Quadrivalent Meningococcal Vaccine Product Portfolios and Specifications
13.5.3 Zhejiang Tianyuan Biopharmaceutical Co., Ltd. Quadrivalent Meningococcal Vaccine Sales, Revenue, Price and Gross Margin (2018-2023)
13.5.4 Zhejiang Tianyuan Biopharmaceutical Co., Ltd. Main Business Overview
13.5.5 Zhejiang Tianyuan Biopharmaceutical Co., Ltd. Latest Developments
13.6 Beijing Institute of Biological Products Co., Ltd.
13.6.1 Beijing Institute of Biological Products Co., Ltd. Company Information
13.6.2 Beijing Institute of Biological Products Co., Ltd. Quadrivalent Meningococcal Vaccine Product Portfolios and Specifications
13.6.3 Beijing Institute of Biological Products Co., Ltd. Quadrivalent Meningococcal Vaccine Sales, Revenue, Price and Gross Margin (2018-2023)
13.6.4 Beijing Institute of Biological Products Co., Ltd. Main Business Overview
13.6.5 Beijing Institute of Biological Products Co., Ltd. Latest Developments
13.7 CanSino Biological Co., Ltd.
13.7.1 CanSino Biological Co., Ltd. Company Information
13.7.2 CanSino Biological Co., Ltd. Quadrivalent Meningococcal Vaccine Product Portfolios and Specifications
13.7.3 CanSino Biological Co., Ltd. Quadrivalent Meningococcal Vaccine Sales, Revenue, Price and Gross Margin (2018-2023)
13.7.4 CanSino Biological Co., Ltd. Main Business Overview
13.7.5 CanSino Biological Co., Ltd. Latest Developments
13.8 Hualan Biological Vaccine Co., Ltd.
13.8.1 Hualan Biological Vaccine Co., Ltd. Company Information
13.8.2 Hualan Biological Vaccine Co., Ltd. Quadrivalent Meningococcal Vaccine Product Portfolios and Specifications
13.8.3 Hualan Biological Vaccine Co., Ltd. Quadrivalent Meningococcal Vaccine Sales, Revenue, Price and Gross Margin (2018-2023)
13.8.4 Hualan Biological Vaccine Co., Ltd. Main Business Overview
13.8.5 Hualan Biological Vaccine Co., Ltd. Latest Developments
13.9 Amy Weixin Biopharmaceutical (Zhejiang) Co., Ltd.
13.9.1 Amy Weixin Biopharmaceutical (Zhejiang) Co., Ltd. Company Information
13.9.2 Amy Weixin Biopharmaceutical (Zhejiang) Co., Ltd. Quadrivalent Meningococcal Vaccine Product Portfolios and Specifications
13.9.3 Amy Weixin Biopharmaceutical (Zhejiang) Co., Ltd. Quadrivalent Meningococcal Vaccine Sales, Revenue, Price and Gross Margin (2018-2023)
13.9.4 Amy Weixin Biopharmaceutical (Zhejiang) Co., Ltd. Main Business Overview
13.9.5 Amy Weixin Biopharmaceutical (Zhejiang) Co., Ltd. Latest Developments
14 Research Findings and Conclusion

List of Tables
Table 1. Quadrivalent Meningococcal Vaccine Annual Sales CAGR by Geographic Region (2018, 2022 & 2029) & ($ millions)
Table 2. Quadrivalent Meningococcal Vaccine Annual Sales CAGR by Country/Region (2018, 2022 & 2029) & ($ millions)
Table 3. Major Players of Polysaccharide Vaccine
Table 4. Major Players of Conjugate Vaccine
Table 5. Global Quadrivalent Meningococcal Vaccine Sales by Type (2018-2023) & (K Units)
Table 6. Global Quadrivalent Meningococcal Vaccine Sales Market Share by Type (2018-2023)
Table 7. Global Quadrivalent Meningococcal Vaccine Revenue by Type (2018-2023) & ($ million)
Table 8. Global Quadrivalent Meningococcal Vaccine Revenue Market Share by Type (2018-2023)
Table 9. Global Quadrivalent Meningococcal Vaccine Sale Price by Type (2018-2023) & (US$/Unit)
Table 10. Global Quadrivalent Meningococcal Vaccine Sales by Application (2018-2023) & (K Units)
Table 11. Global Quadrivalent Meningococcal Vaccine Sales Market Share by Application (2018-2023)
Table 12. Global Quadrivalent Meningococcal Vaccine Revenue by Application (2018-2023)
Table 13. Global Quadrivalent Meningococcal Vaccine Revenue Market Share by Application (2018-2023)
Table 14. Global Quadrivalent Meningococcal Vaccine Sale Price by Application (2018-2023) & (US$/Unit)
Table 15. Global Quadrivalent Meningococcal Vaccine Sales by Company (2018-2023) & (K Units)
Table 16. Global Quadrivalent Meningococcal Vaccine Sales Market Share by Company (2018-2023)
Table 17. Global Quadrivalent Meningococcal Vaccine Revenue by Company (2018-2023) ($ Millions)
Table 18. Global Quadrivalent Meningococcal Vaccine Revenue Market Share by Company (2018-2023)
Table 19. Global Quadrivalent Meningococcal Vaccine Sale Price by Company (2018-2023) & (US$/Unit)
Table 20. Key Manufacturers Quadrivalent Meningococcal Vaccine Producing Area Distribution and Sales Area
Table 21. Players Quadrivalent Meningococcal Vaccine Products Offered
Table 22. Quadrivalent Meningococcal Vaccine Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
Table 23. New Products and Potential Entrants
Table 24. Mergers & Acquisitions, Expansion
Table 25. Global Quadrivalent Meningococcal Vaccine Sales by Geographic Region (2018-2023) & (K Units)
Table 26. Global Quadrivalent Meningococcal Vaccine Sales Market Share Geographic Region (2018-2023)
Table 27. Global Quadrivalent Meningococcal Vaccine Revenue by Geographic Region (2018-2023) & ($ millions)
Table 28. Global Quadrivalent Meningococcal Vaccine Revenue Market Share by Geographic Region (2018-2023)
Table 29. Global Quadrivalent Meningococcal Vaccine Sales by Country/Region (2018-2023) & (K Units)
Table 30. Global Quadrivalent Meningococcal Vaccine Sales Market Share by Country/Region (2018-2023)
Table 31. Global Quadrivalent Meningococcal Vaccine Revenue by Country/Region (2018-2023) & ($ millions)
Table 32. Global Quadrivalent Meningococcal Vaccine Revenue Market Share by Country/Region (2018-2023)
Table 33. Americas Quadrivalent Meningococcal Vaccine Sales by Country (2018-2023) & (K Units)
Table 34. Americas Quadrivalent Meningococcal Vaccine Sales Market Share by Country (2018-2023)
Table 35. Americas Quadrivalent Meningococcal Vaccine Revenue by Country (2018-2023) & ($ Millions)
Table 36. Americas Quadrivalent Meningococcal Vaccine Revenue Market Share by Country (2018-2023)
Table 37. Americas Quadrivalent Meningococcal Vaccine Sales by Type (2018-2023) & (K Units)
Table 38. Americas Quadrivalent Meningococcal Vaccine Sales by Application (2018-2023) & (K Units)
Table 39. APAC Quadrivalent Meningococcal Vaccine Sales by Region (2018-2023) & (K Units)
Table 40. APAC Quadrivalent Meningococcal Vaccine Sales Market Share by Region (2018-2023)
Table 41. APAC Quadrivalent Meningococcal Vaccine Revenue by Region (2018-2023) & ($ Millions)
Table 42. APAC Quadrivalent Meningococcal Vaccine Revenue Market Share by Region (2018-2023)
Table 43. APAC Quadrivalent Meningococcal Vaccine Sales by Type (2018-2023) & (K Units)
Table 44. APAC Quadrivalent Meningococcal Vaccine Sales by Application (2018-2023) & (K Units)
Table 45. Europe Quadrivalent Meningococcal Vaccine Sales by Country (2018-2023) & (K Units)
Table 46. Europe Quadrivalent Meningococcal Vaccine Sales Market Share by Country (2018-2023)
Table 47. Europe Quadrivalent Meningococcal Vaccine Revenue by Country (2018-2023) & ($ Millions)
Table 48. Europe Quadrivalent Meningococcal Vaccine Revenue Market Share by Country (2018-2023)
Table 49. Europe Quadrivalent Meningococcal Vaccine Sales by Type (2018-2023) & (K Units)
Table 50. Europe Quadrivalent Meningococcal Vaccine Sales by Application (2018-2023) & (K Units)
Table 51. Middle East & Africa Quadrivalent Meningococcal Vaccine Sales by Country (2018-2023) & (K Units)
Table 52. Middle East & Africa Quadrivalent Meningococcal Vaccine Sales Market Share by Country (2018-2023)
Table 53. Middle East & Africa Quadrivalent Meningococcal Vaccine Revenue by Country (2018-2023) & ($ Millions)
Table 54. Middle East & Africa Quadrivalent Meningococcal Vaccine Revenue Market Share by Country (2018-2023)
Table 55. Middle East & Africa Quadrivalent Meningococcal Vaccine Sales by Type (2018-2023) & (K Units)
Table 56. Middle East & Africa Quadrivalent Meningococcal Vaccine Sales by Application (2018-2023) & (K Units)
Table 57. Key Market Drivers & Growth Opportunities of Quadrivalent Meningococcal Vaccine
Table 58. Key Market Challenges & Risks of Quadrivalent Meningococcal Vaccine
Table 59. Key Industry Trends of Quadrivalent Meningococcal Vaccine
Table 60. Quadrivalent Meningococcal Vaccine Raw Material
Table 61. Key Suppliers of Raw Materials
Table 62. Quadrivalent Meningococcal Vaccine Distributors List
Table 63. Quadrivalent Meningococcal Vaccine Customer List
Table 64. Global Quadrivalent Meningococcal Vaccine Sales Forecast by Region (2024-2029) & (K Units)
Table 65. Global Quadrivalent Meningococcal Vaccine Revenue Forecast by Region (2024-2029) & ($ millions)
Table 66. Americas Quadrivalent Meningococcal Vaccine Sales Forecast by Country (2024-2029) & (K Units)
Table 67. Americas Quadrivalent Meningococcal Vaccine Revenue Forecast by Country (2024-2029) & ($ millions)
Table 68. APAC Quadrivalent Meningococcal Vaccine Sales Forecast by Region (2024-2029) & (K Units)
Table 69. APAC Quadrivalent Meningococcal Vaccine Revenue Forecast by Region (2024-2029) & ($ millions)
Table 70. Europe Quadrivalent Meningococcal Vaccine Sales Forecast by Country (2024-2029) & (K Units)
Table 71. Europe Quadrivalent Meningococcal Vaccine Revenue Forecast by Country (2024-2029) & ($ millions)
Table 72. Middle East & Africa Quadrivalent Meningococcal Vaccine Sales Forecast by Country (2024-2029) & (K Units)
Table 73. Middle East & Africa Quadrivalent Meningococcal Vaccine Revenue Forecast by Country (2024-2029) & ($ millions)
Table 74. Global Quadrivalent Meningococcal Vaccine Sales Forecast by Type (2024-2029) & (K Units)
Table 75. Global Quadrivalent Meningococcal Vaccine Revenue Forecast by Type (2024-2029) & ($ Millions)
Table 76. Global Quadrivalent Meningococcal Vaccine Sales Forecast by Application (2024-2029) & (K Units)
Table 77. Global Quadrivalent Meningococcal Vaccine Revenue Forecast by Application (2024-2029) & ($ Millions)
Table 78. Sanofi-Pasteur Basic Information, Quadrivalent Meningococcal Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 79. Sanofi-Pasteur Quadrivalent Meningococcal Vaccine Product Portfolios and Specifications
Table 80. Sanofi-Pasteur Quadrivalent Meningococcal Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 81. Sanofi-Pasteur Main Business
Table 82. Sanofi-Pasteur Latest Developments
Table 83. Walvax Basic Information, Quadrivalent Meningococcal Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 84. Walvax Quadrivalent Meningococcal Vaccine Product Portfolios and Specifications
Table 85. Walvax Quadrivalent Meningococcal Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 86. Walvax Main Business
Table 87. Walvax Latest Developments
Table 88. Chengdu Kanghua Biological Products Co., Ltd. Basic Information, Quadrivalent Meningococcal Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 89. Chengdu Kanghua Biological Products Co., Ltd. Quadrivalent Meningococcal Vaccine Product Portfolios and Specifications
Table 90. Chengdu Kanghua Biological Products Co., Ltd. Quadrivalent Meningococcal Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 91. Chengdu Kanghua Biological Products Co., Ltd. Main Business
Table 92. Chengdu Kanghua Biological Products Co., Ltd. Latest Developments
Table 93. Beijing Zhifei Green Bamboo Biopharmaceutical Co., Ltd. Basic Information, Quadrivalent Meningococcal Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 94. Beijing Zhifei Green Bamboo Biopharmaceutical Co., Ltd. Quadrivalent Meningococcal Vaccine Product Portfolios and Specifications
Table 95. Beijing Zhifei Green Bamboo Biopharmaceutical Co., Ltd. Quadrivalent Meningococcal Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 96. Beijing Zhifei Green Bamboo Biopharmaceutical Co., Ltd. Main Business
Table 97. Beijing Zhifei Green Bamboo Biopharmaceutical Co., Ltd. Latest Developments
Table 98. Zhejiang Tianyuan Biopharmaceutical Co., Ltd. Basic Information, Quadrivalent Meningococcal Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 99. Zhejiang Tianyuan Biopharmaceutical Co., Ltd. Quadrivalent Meningococcal Vaccine Product Portfolios and Specifications
Table 100. Zhejiang Tianyuan Biopharmaceutical Co., Ltd. Quadrivalent Meningococcal Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 101. Zhejiang Tianyuan Biopharmaceutical Co., Ltd. Main Business
Table 102. Zhejiang Tianyuan Biopharmaceutical Co., Ltd. Latest Developments
Table 103. Beijing Institute of Biological Products Co., Ltd. Basic Information, Quadrivalent Meningococcal Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 104. Beijing Institute of Biological Products Co., Ltd. Quadrivalent Meningococcal Vaccine Product Portfolios and Specifications
Table 105. Beijing Institute of Biological Products Co., Ltd. Quadrivalent Meningococcal Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 106. Beijing Institute of Biological Products Co., Ltd. Main Business
Table 107. Beijing Institute of Biological Products Co., Ltd. Latest Developments
Table 108. CanSino Biological Co., Ltd. Basic Information, Quadrivalent Meningococcal Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 109. CanSino Biological Co., Ltd. Quadrivalent Meningococcal Vaccine Product Portfolios and Specifications
Table 110. CanSino Biological Co., Ltd. Quadrivalent Meningococcal Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 111. CanSino Biological Co., Ltd. Main Business
Table 112. CanSino Biological Co., Ltd. Latest Developments
Table 113. Hualan Biological Vaccine Co., Ltd. Basic Information, Quadrivalent Meningococcal Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 114. Hualan Biological Vaccine Co., Ltd. Quadrivalent Meningococcal Vaccine Product Portfolios and Specifications
Table 115. Hualan Biological Vaccine Co., Ltd. Quadrivalent Meningococcal Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 116. Hualan Biological Vaccine Co., Ltd. Main Business
Table 117. Hualan Biological Vaccine Co., Ltd. Latest Developments
Table 118. Amy Weixin Biopharmaceutical (Zhejiang) Co., Ltd. Basic Information, Quadrivalent Meningococcal Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 119. Amy Weixin Biopharmaceutical (Zhejiang) Co., Ltd. Quadrivalent Meningococcal Vaccine Product Portfolios and Specifications
Table 120. Amy Weixin Biopharmaceutical (Zhejiang) Co., Ltd. Quadrivalent Meningococcal Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 121. Amy Weixin Biopharmaceutical (Zhejiang) Co., Ltd. Main Business
Table 122. Amy Weixin Biopharmaceutical (Zhejiang) Co., Ltd. Latest Developments
List of Figures
Figure 1. Picture of Quadrivalent Meningococcal Vaccine
Figure 2. Quadrivalent Meningococcal Vaccine Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Quadrivalent Meningococcal Vaccine Sales Growth Rate 2018-2029 (K Units)
Figure 7. Global Quadrivalent Meningococcal Vaccine Revenue Growth Rate 2018-2029 ($ Millions)
Figure 8. Quadrivalent Meningococcal Vaccine Sales by Region (2018, 2022 & 2029) & ($ Millions)
Figure 9. Product Picture of Polysaccharide Vaccine
Figure 10. Product Picture of Conjugate Vaccine
Figure 11. Global Quadrivalent Meningococcal Vaccine Sales Market Share by Type in 2022
Figure 12. Global Quadrivalent Meningococcal Vaccine Revenue Market Share by Type (2018-2023)
Figure 13. Quadrivalent Meningococcal Vaccine Consumed in Hospital
Figure 14. Global Quadrivalent Meningococcal Vaccine Market: Hospital (2018-2023) & (K Units)
Figure 15. Quadrivalent Meningococcal Vaccine Consumed in Clinic
Figure 16. Global Quadrivalent Meningococcal Vaccine Market: Clinic (2018-2023) & (K Units)
Figure 17. Global Quadrivalent Meningococcal Vaccine Sales Market Share by Application (2022)
Figure 18. Global Quadrivalent Meningococcal Vaccine Revenue Market Share by Application in 2022
Figure 19. Quadrivalent Meningococcal Vaccine Sales Market by Company in 2022 (K Units)
Figure 20. Global Quadrivalent Meningococcal Vaccine Sales Market Share by Company in 2022
Figure 21. Quadrivalent Meningococcal Vaccine Revenue Market by Company in 2022 ($ Million)
Figure 22. Global Quadrivalent Meningococcal Vaccine Revenue Market Share by Company in 2022
Figure 23. Global Quadrivalent Meningococcal Vaccine Sales Market Share by Geographic Region (2018-2023)
Figure 24. Global Quadrivalent Meningococcal Vaccine Revenue Market Share by Geographic Region in 2022
Figure 25. Americas Quadrivalent Meningococcal Vaccine Sales 2018-2023 (K Units)
Figure 26. Americas Quadrivalent Meningococcal Vaccine Revenue 2018-2023 ($ Millions)
Figure 27. APAC Quadrivalent Meningococcal Vaccine Sales 2018-2023 (K Units)
Figure 28. APAC Quadrivalent Meningococcal Vaccine Revenue 2018-2023 ($ Millions)
Figure 29. Europe Quadrivalent Meningococcal Vaccine Sales 2018-2023 (K Units)
Figure 30. Europe Quadrivalent Meningococcal Vaccine Revenue 2018-2023 ($ Millions)
Figure 31. Middle East & Africa Quadrivalent Meningococcal Vaccine Sales 2018-2023 (K Units)
Figure 32. Middle East & Africa Quadrivalent Meningococcal Vaccine Revenue 2018-2023 ($ Millions)
Figure 33. Americas Quadrivalent Meningococcal Vaccine Sales Market Share by Country in 2022
Figure 34. Americas Quadrivalent Meningococcal Vaccine Revenue Market Share by Country in 2022
Figure 35. Americas Quadrivalent Meningococcal Vaccine Sales Market Share by Type (2018-2023)
Figure 36. Americas Quadrivalent Meningococcal Vaccine Sales Market Share by Application (2018-2023)
Figure 37. United States Quadrivalent Meningococcal Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 38. Canada Quadrivalent Meningococcal Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 39. Mexico Quadrivalent Meningococcal Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 40. Brazil Quadrivalent Meningococcal Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 41. APAC Quadrivalent Meningococcal Vaccine Sales Market Share by Region in 2022
Figure 42. APAC Quadrivalent Meningococcal Vaccine Revenue Market Share by Regions in 2022
Figure 43. APAC Quadrivalent Meningococcal Vaccine Sales Market Share by Type (2018-2023)
Figure 44. APAC Quadrivalent Meningococcal Vaccine Sales Market Share by Application (2018-2023)
Figure 45. China Quadrivalent Meningococcal Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 46. Japan Quadrivalent Meningococcal Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 47. South Korea Quadrivalent Meningococcal Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 48. Southeast Asia Quadrivalent Meningococcal Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 49. India Quadrivalent Meningococcal Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 50. Australia Quadrivalent Meningococcal Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 51. China Taiwan Quadrivalent Meningococcal Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 52. Europe Quadrivalent Meningococcal Vaccine Sales Market Share by Country in 2022
Figure 53. Europe Quadrivalent Meningococcal Vaccine Revenue Market Share by Country in 2022
Figure 54. Europe Quadrivalent Meningococcal Vaccine Sales Market Share by Type (2018-2023)
Figure 55. Europe Quadrivalent Meningococcal Vaccine Sales Market Share by Application (2018-2023)
Figure 56. Germany Quadrivalent Meningococcal Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 57. France Quadrivalent Meningococcal Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 58. UK Quadrivalent Meningococcal Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 59. Italy Quadrivalent Meningococcal Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 60. Russia Quadrivalent Meningococcal Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 61. Middle East & Africa Quadrivalent Meningococcal Vaccine Sales Market Share by Country in 2022
Figure 62. Middle East & Africa Quadrivalent Meningococcal Vaccine Revenue Market Share by Country in 2022
Figure 63. Middle East & Africa Quadrivalent Meningococcal Vaccine Sales Market Share by Type (2018-2023)
Figure 64. Middle East & Africa Quadrivalent Meningococcal Vaccine Sales Market Share by Application (2018-2023)
Figure 65. Egypt Quadrivalent Meningococcal Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 66. South Africa Quadrivalent Meningococcal Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 67. Israel Quadrivalent Meningococcal Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 68. Turkey Quadrivalent Meningococcal Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 69. GCC Country Quadrivalent Meningococcal Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 70. Manufacturing Cost Structure Analysis of Quadrivalent Meningococcal Vaccine in 2022
Figure 71. Manufacturing Process Analysis of Quadrivalent Meningococcal Vaccine
Figure 72. Industry Chain Structure of Quadrivalent Meningococcal Vaccine
Figure 73. Channels of Distribution
Figure 74. Global Quadrivalent Meningococcal Vaccine Sales Market Forecast by Region (2024-2029)
Figure 75. Global Quadrivalent Meningococcal Vaccine Revenue Market Share Forecast by Region (2024-2029)
Figure 76. Global Quadrivalent Meningococcal Vaccine Sales Market Share Forecast by Type (2024-2029)
Figure 77. Global Quadrivalent Meningococcal Vaccine Revenue Market Share Forecast by Type (2024-2029)
Figure 78. Global Quadrivalent Meningococcal Vaccine Sales Market Share Forecast by Application (2024-2029)
Figure 79. Global Quadrivalent Meningococcal Vaccine Revenue Market Share Forecast by Application (2024-2029)


★調査レポート[世界の4価髄膜炎菌ワクチン市場予測 2023年-2029年] (コード:LP23DC00098)販売に関する免責事項を必ずご確認ください。
★調査レポート[世界の4価髄膜炎菌ワクチン市場予測 2023年-2029年]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆